Fidelity SPDR Advertisement
Home > Boards > US OTC > Medical - Equipment >

Cytosorbents Corporation (CTSO)

Add CTSO Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator BuyMyAsk, dr_lowenstein
Search This Board:
Last Post: 9/19/2014 1:21:09 AM - Followers: 174 - Board type: Free - Posts Today: 2
About CytoSorbents, CytoSorb, and HemoDefend

CytoSorbents Corporation is a critical care focused therapeutic device company using blood purification to modulate the immune system and fight multi-organ failure in life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. In 2011, CytoSorb®, the Company's flagship product, achieved European regulatory approval as an extracorporeal cytokine filter, allowing it to be sold throughout the European Union (E.U.) under the CE Mark, to be used in clinical situations where cytokines are elevated. The goal of the CytoSorb® cytokine filter is to reduce "cytokine storm" in critically-ill patients that could otherwise lead to deadly inflammation, multiple organ failure, immune dysfunction, and often death in common illnesses such as sepsis, trauma, burn injury, acute respiratory distress syndrome, and pancreatitis. The CytoSorb® filter has demonstrated statistically significant reductions in mortality in septic patients at high risk of death in early studies and is now being sold in Germany, Austria and Switzerland for the treatment of critical care illnesses, with availability in other E.U. countries planned in the future, assuming adequate and timely funding, and continued positive results from clinical studies.

HemoDefend is a development-stage blood purification technology platform for the blood transfusion industry intended to reduce transfusion reactions and safeguard the quality and safety of the blood supply. The HemoDefend technology utilizes the Company's polymer bead technology to remove many substances, such as antibodies, free hemoglobin and inflammatory mediators that can cause potentially serious and sometimes fatal transfusion reactions.

CytoSorb® and HemoDefend are just two of a number of different polymers the Company has designed for various medical applications, including improved dialysis, reduction of post-surgical complications in cardiac surgery, treatment of inflammatory and autoimmune disorders, radio-imaging contrast removal in imaging and interventional radiology procedures, and the treatment of rhabdomyolysis, drug overdose, and others. Additional information is available for download on the Company's website:


CytoSorb® - A First-in-Class Cytokine Filter Approved in the European Union


CytoSorb® is a potentially breakthrough critical care immunotherapy that attempts to address one of the most challenging unmet medical needs in medicine…the ability to prevent or mitigate multiple organ failure - the leading cause of death in the intensive care unit (ICU) from any cause.

In response to life-threatening conditions such as sepsis and infection, trauma, serious burn injuries, severe lung injury, and pancreatitis, the body frequently overreacts and produces a massive excess of cytokines, or “cytokine storm”. Cytokines normally help the body cope with injury, but at these levels, cytokine storm is toxic to the body, driving severe inflammation and a cascade of pathophysiologic changes in the body that cause cell damage, organ failure and often death. It follows that reduction of cytokine storm may limit this cascade of events, thereby reducing the severity of illness, and helping patients recover and survive. Until recently, however, there were no effective ways to reduce cytokine storm broadly.

CytoSorb® is a first-in-class extracorporeal cytokine filter, now approved in the European Union, and broadly indicated for use in any clinical situation where cytokines are elevated. It is compatible with standard hemodialysis machines and blood pumps found in most hospitals. Blood is pumped out of the body, through the CytoSorb® cartridge that contains the company’s proprietary blood compatible porous polymer beads, and the “purified” blood is recirculated back to the patient. In a six hour period, a patient's entire blood volume can be treated approximately 20 times.

CytoSorb® is clinically proven to reduce cytokine storm in the company's multi-center, randomized, controlled European Sepsis Trial conducted in Germany. Treatment was safe and well-tolerated in more than 300 human treatments in very sick patients with the worst forms of sepsis and lung injury, and treatment has been safe in nearly 1,500 human treatments overall. Early data suggests that CytoSorb® can reduce organ injury and improve survival in patients at high risk of cytokine injury, particularly those patients with very high cytokine levels, and patients older than age 65.

CytoSorb® has now been used successfully in many conditions where deadly inflammation can lead to organ injury and failure. We are seeing strong interest in the following clinical applications:


There are more than 100 key opinion leaders in Germany, Austria, and Switzerland (our direct sales territories) who are either using or committed to using CytoSorb in clinical practice or clinical studies. More than 30 investigator-initiated studies in a diverse set of applications are being planned, with many already enrolling patients. In the United States, the U.S. Air Force is funding a 30-patient, FDA-approved randomized controlled human trauma pilot study.

As these other independent studies progress, CytoSorbents collaborates with Dr. John Kellum at the University of Pittsburgh Medical Center, and is sponsoring clinical studies in the area of severe sepsis and septic shock, the result of an overzealous immune response to a severe infection such as pneumonia or a ruptured appendix. Severe sepsis and septic shock are collectively a top ten cause of death worldwide, afflicting approximately 27 million people annually, killing approximately 1 in 3 patients despite the best medical care. CytoSorbents is conducting clinical trials in Europea and currently has an FDA-approved IDE application to run a small sepsis trial in the U.S.. The company will look to conduct a U.S. pivotal sepsis study in the future as a key step towards U.S. FDA approval.

Because of the versatility of CytoSorb®, there are many other potential applications of the technology outside of critical care medicine as well. In particular, CytoSorb® has been used many times intraoperatively during open heart surgery, where the heart must be stopped in order to operate on it, while the blood is pumped outside of the body by a heart-lung machine that oxygenates the blood and pumps it back to the rest of the body. This procedure can result in the production of inflammatory mediators such as cytokines, as well as hemolysis and the release of free hemoglobin into the blood. This can result in inflammation and post-operative complications such as failure to wean from mechanical ventilation and kidney failure. There are more than 1 million open heart surgeries each year in the U.S. and E.U. combined, with an addressable market of more than $1 billion for CytoSorb®.

Another application is in cancer immunotherapy. Cancer cachexia is a wasting condition that occurs in most cancers that leads to rapid uncontrolled weight loss, anorexia, and physical debilitation. Patients lose the physical reserve needed to tolerate treatment and fight the cancer. Because CytoSorb® can remove a broad range of cytokines and other inflammatory mediators that drive cancer cachexia, it may be very helpful in this condition. CytoSorbents is exploring this application, as well as the use of CytoSorb® as a primary cancer immunotherapy to kickstart the immune system to attack cancer, with researchers at the University of Pennsylvania School of Veterinary Medicine.

CytoSorb® is being sold for clinical use in the European Union and in countries outside of the European Union that accept European CE Mark approval such as India, Russia, Turkey and others. The total addressable market for CytoSorb® in critical care applications such as sepsis, burn injury, trauma, ARDS, pancreatitis and other diseases is estimated at $10-15 Billion in the U.S. and Europe alone.


From Shareholder's Letter

Goals for 2014

We have laid out an ambitious, yet potentially achievable, agenda for the next two years. Some of our highest priorities are:

  • Greater awareness of our story and technology through increased media exposure and improved investor relations
  • Revenue growth and increased product adoption in our direct sales territories
  • Distributor agreements for CytoSorb in Europe and elsewhere
  • Strategic partnerships for our pipeline products
  • Non-dilutive funding from grants and other programs
  • Commencement of a U.S. based trial
  • Clinical data and new clinical applications with data being presented at key scientific conferences
  • Improving liquidity and institutional sponsorship of our stock with potential up-listing to a national stock exchange

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
CTSO News: CytoSorbents Proudly Sponsors World Sepsis Day 2014, Celebration of Sepsis Heroes, and the Roger Bone Award 09/18/2014 07:00:00 AM
CTSO News: Statement of Changes in Beneficial Ownership (4) 09/16/2014 03:37:26 PM
CTSO News: Statement of Changes in Beneficial Ownership (4) 09/15/2014 05:15:09 PM
CTSO News: Statement of Changes in Beneficial Ownership (4) 09/09/2014 05:30:48 PM
CTSO News: Statement of Changes in Beneficial Ownership (4) 09/09/2014 04:40:03 PM
News News Alert: CytoSorbents Proudly Sponsors World Sepsis Day 2014, Celebration of Sepsis Heroes, and the Roger Bone Award 09/18/2014 07:00:00 AM
#5727   Got this from an article on the aemd bd. Murph1953 09/19/14 01:21:09 AM
#5726   Die Welt, ( German: “The World”) daily newspaper, Murph1953 09/19/14 12:48:13 AM
#5725   Thanks Ping Pow WishfulThinking1 09/18/14 08:51:13 AM
#5724   WOW one MD tells another MD about Cytosorbents Paulness 09/17/14 11:02:59 PM
#5723 andy55q 09/17/14 09:58:04 PM
#5722   Global threat to humanity ping_pow_princess 09/17/14 09:49:21 PM
#5721   Link please Paulness 09/17/14 08:46:32 PM
#5720   What is exactly is still difficult to discern. andy55q 09/17/14 07:42:06 PM
#5719   Use of the HP or the CS filter? Murph1953 09/16/14 02:11:12 PM
#5718   You always provide useful unbiased info, thank you andy! WishfulThinking1 09/15/14 10:35:54 PM
#5717   All real shareholders are serious , its been Paulness 09/15/14 05:27:19 PM
#5716   LOL - "GEM" BuyMyAsk 09/15/14 05:07:53 PM
#5715   LINC MEDICAL SYSTEMS ANNOUNCES THE andy55q 09/14/14 07:47:34 PM
#5714   Paulness- Which other board? I'm only aware of bkmomail 09/14/14 10:07:42 AM
#5713   WMC Medical Supplies & Consultancy andy55q 09/13/14 04:33:06 PM
#5712   Paulness I know Cytosorbents quite well. I have been snow 09/13/14 02:20:24 AM
#5711   Very nice I posted it on the other Paulness 09/12/14 11:06:10 PM
#5710   Third job posting in India for CytoSorb task force: ping_pow_princess 09/12/14 06:31:03 PM
#5709   I don't know if you know that Cytosorbents Paulness 09/12/14 04:13:17 PM
#5708   Paulness How can profits increase when there are no snow 09/12/14 04:07:33 PM
#5707   That's unfortunate because a trial with a few pharmeng 09/11/14 07:42:51 PM
#5706   Nice day today 90% buys ! Paulness 09/11/14 04:21:16 PM
#5705   I would be WOW'ed with 2 consecutive quarters BuyMyAsk 09/11/14 03:01:14 PM
#5704   What will WOW you ,just remember only 3000 Paulness 09/11/14 01:13:56 PM
#5703   pharmeng - excellent post and questions. It BuyMyAsk 09/11/14 12:41:24 PM
#5702   As I have stated before and as I BuyMyAsk 09/11/14 12:38:01 PM
#5701   Hahaha... Paulness have you been around long? BuyMyAsk 09/11/14 12:34:39 PM
#5700   By and large that is what Cytosorbents will be. Paulness 09/11/14 11:29:48 AM
#5699   By and large I agree with you. Bikle 09/11/14 08:51:36 AM
#5698   BMA How do you think they will continue to pharmeng 09/10/14 10:58:30 PM
#5697   CTSO An absolute monster stock in the making Paulness 09/10/14 09:41:15 PM
#5696   Official cause of death ruled in mysterious death andy55q 09/10/14 04:35:28 PM
#5695   Bikle - there is noooo way we can BuyMyAsk 09/09/14 05:11:39 PM
#5694   I do not always agree with you but... Bikle 09/09/14 10:21:29 AM
#5693   Dah - I disagree with you. BuyMyAsk 09/09/14 09:46:33 AM
#5692   Enough already! This is not fluff. You keep dah174174 09/09/14 09:25:44 AM
#5691   Thanks for letting me know you have a BuyMyAsk 09/09/14 09:05:13 AM
#5690   CytoSorbents to Present at the 2014 Rodman & Paulness 09/08/14 11:38:14 PM
#5689   BuymyAsk, welcome always. As a small stockholder, most Glimmer Man 09/08/14 03:34:49 PM
#5688   How is the price in the chitter for malc stone 09/06/14 03:33:54 PM
#5687   CTSO - Need to get to a tipping The_Free_Nebula 09/06/14 10:37:11 AM
#5686   They (insiders) seem to be cashing in while The_Free_Nebula 09/06/14 10:32:10 AM
#5685   Does anybody else think that Cytosorbents is charging Paulness 09/05/14 08:57:54 PM
#5684   We are not going to see flat sales dah174174 09/05/14 04:59:32 PM
#5683   Agree 100%. Very Sad when good folks smitter 09/05/14 10:55:54 AM
#5682   I never met Joe personally but during the BuyMyAsk 09/05/14 10:54:58 AM
#5681   Dah it seems you are more educated than BuyMyAsk 09/05/14 10:39:25 AM
#5680   I believe all that is going on with dah174174 09/05/14 09:02:07 AM
#5679   RIP Joe :( smitter 09/05/14 08:58:24 AM
#5678   You have to do your DD Paulness 09/04/14 10:11:54 PM